950130 — Access Bio Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -0.86% | ||
| Return on Equity | -0.06% | ||
| Operating Margin | -5% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 103.21 | 441.37 | 800.23 | 267.08 | 82.45 | n/a | n/a | 17.42% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | +262.73 | +59.05 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Access Bio, Inc. focuses on preventing and diagnosing infectious diseases early through research, development, and manufacturing of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products. The Company also launched diagnostic products, including tests for Coronavirus Disease 2019 (COVID-19), Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, dengue fever, influenza, and strep. The Company has commercialized products to combat malaria and other diseases. The Company’s product lineup includes COVID-19 Detection Kits -These kits assess the current or past presence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2); Rapid Diagnostic Tests (RDTs) - RDTs are used for preliminary diagnosis or emergency medical screening in facilities with limited resources; Analyzers - Designed to measure various chemicals and characteristics in biological samples; and Molecular Diagnostics - These are used to analyze biological markers in the genome and proteome.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 27th, 2002
- Public Since
- May 30th, 2013
- No. of Shareholders
- 37,076
- No. of Employees
- 63
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Korea Exchange - KOSDAQ
- Address
- 65 CLYDE ROAD, SUITE A, SOMERSET, 08873
- Web
- https://accessbio.net/
- Phone
- +1 7328734040
- Auditors
- Woori Accountants
Upcoming Events for 950130
Similar to 950130
Aligned Genetics
Korea Exchange - KOSDAQ
Alphanox Co
Korea Exchange - KOSDAQ
Angel Robotics Co
Korea Exchange - KOSDAQ
Asta Co
Korea Exchange - KOSDAQ
Asterasys Co
Korea Exchange - KOSDAQ
FAQ
As of Today at 19:03 UTC, shares in Access Bio are trading at KR₩5,030. This share price information is delayed by 15 minutes.
Shares in Access Bio last closed at KR₩5,030 and the price had moved by -21.16% over the past 365 days. In terms of relative price strength the Access Bio share price has underperformed the FTSE Developed Asia Pacific Index by -20.26% over the past year.
There is no consensus recommendation for this security.
Find out moreAccess Bio does not currently pay a dividend.
Access Bio does not currently pay a dividend.
Access Bio does not currently pay a dividend.
To buy shares in Access Bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩5,030, shares in Access Bio had a market capitalisation of .
Here are the trading details for Access Bio:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 950130
Based on an overall assessment of its quality, value and momentum Access Bio is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Access Bio. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -11.61%.
As of the last closing price of KR₩5,030, shares in Access Bio were trading -16.22% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Access Bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩5,030.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Access Bio's directors